Doctors suggest new names for low-grade prostate cancer
A cancer diagnosis is scary. Some doctors say it's time to rename low-grade prostate cancer to eliminate the alarming C-word.
Apr 18, 2022
0
148
A cancer diagnosis is scary. Some doctors say it's time to rename low-grade prostate cancer to eliminate the alarming C-word.
Apr 18, 2022
0
148
Hepatocellular carcinoma (HCC) is the most primary liver cancer. It is one of the most common and deadly cancer worldwide, especially in East Asia. Advanced HCC patients expect a significantly low 5-year survival rate as ...
Apr 18, 2022
0
2
Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.
Apr 13, 2022
0
62
Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified. A drug used ...
Apr 11, 2022
0
21
San Diego startup AltheaDx, which developed a molecular test designed to guide therapy for depression and anxiety based on a patient's genetics, is being acquired for $65 million in stock and cash.
Apr 7, 2022
0
3
A new paper in Nature Communications reveals new insights into adaptations made by cancer cells to rewire their metabolism to achieve growth and survive. Among the discoveries include a challenge to a well-known feature in ...
Mar 23, 2022
0
8
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for melanoma and other skin cancers, according to research published today in JAMA Dermatology.
Feb 23, 2022
0
1
A cancer pill, preferably without severe side effects, is something we'd all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves ...
Feb 22, 2022
0
2
(HealthDay)—For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab than with single-agent chemotherapy, according to a study published ...
Feb 11, 2022
0
1
Investigators from UCLA Jonsson Comprehensive Cancer Center have identified a germline biomarker signature that successfully predicts which patients will suffer serious side effects that occur in up to 3 in ten patients on ...
Feb 3, 2022
0
29